Myotonic dystrophy (DM) is the most common form of muscular dystrophy in adults, and is an autosomal dominant disorder characterized by a broad spectrum of clinical features including a dystrophy of unique distribution, myotonia, ocular cataracts, endocrinopathy, and cardiomyopathy. These diverse manifestations are called pleiotropic. Unlike other major muscular dystrophies, DM affects such cranial muscles as the face, external ocular, tongue, temporalis, and sternocleidomastoid (SCM). Atrophy in the temporalis muscle results in "hachet face", and that in SCM, "swan neck". The limb myopathy is the most pronounced distally and affects the hands and feet equally, which eventually involves other proximal muscles. Myotonia can be clinically detected by an opening of the grip (grip myotonia) or by knocking thenar or tongue (percussion myotonia). Cataracts are frequent in these patients. Endocrinopathy includes frontal baldness, testicular atrophy, and diabetes mellitus. Although a conduction abnormality in the heart is frequent, DM is now classified into two subclasses, DM1 and DM2. The phenotypes in DM1 and DM2 are similar, suggesting a shared pathophysiologic mechanism. DM1 is caused by expansion of a CTG trinucleotide repeat in the dystrophia myotonica-protein kinase gene (DMPK) gene on chromosome 19ql3 (1). The affected CTG expansion is located in an intron at the 3' end of the DMPK gene, and the expanded number of intronic CTG is correlated with the severity of symptoms. This trinucleotide expansion is usually unstable between the somatic tissues (somatic instability), although it could be stable in other somatic tissues. In a report in this issue of Internal Medicine, Kinoshita et al (2) reported that the CTG repeat number is high in cancer tissue but not in the normal tissue in a patient with laryngeal and renal double cancer. Even though the CTG expansion itself is not the cause of the cancers, this finding is important to consider the relation between the instability of CTG expansion and cell species (normal vs malignant). 
